Results 121 to 130 of about 759,784 (262)

Systematic review of patient-reported outcome measures for opioid use disorder recovery. [PDF]

Addiction
Pytell JD, Pales D, Simon C, Beaudoin J, Osman AMY, Svoboda E, Christine PJ, Matlock D, Schwartz R, Binswanger IA.   +9 more
europepmc   +1 more source

Patient Reported Outcome Measurements

Journal of Pharmaceutical Research, 2015
openaire   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Readability Analysis of Commonly Cited Patient-Reported Outcome Measures in the Orthopaedic Joint Literature. [PDF]

Arthroplast Today
Uppal H, Garcia D, Rezzadeh K, Sahai N, McGinniss A, Emami A, Rifai A.   +6 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

BMI and its association with patient-reported outcome measures following revision hip surgery. [PDF]

Bone Jt Open
Baumber R, Mehmood A, McCulloch R, Pereira SMP, Warwick E, Hart A, Moonesinghe SR, PQIP delivery team, PQIP collaborative, PQIP delivery team and collaborative, PQIP Delivery Team, Ramani Moonesinghe S, Wagstaff D, Bedford J, Sahni A, McGuckin D, Gilhooly D, Santos C, Wilson J, Martin P, Singleton G, Edwards K, Vindrola-Padros C, Warnakulasuriya S, Dorey J, Leemans I, Martinez D, Lourtie J, Baumber R, Dorey J, Swift A, Jackson A, Belete M, Warwick E, Argent M, Brooks R, Fulop N, Brent A, Williams K, Grocott M, Mythen M, Olive D, Taylor C, Drake S, Swart M, Bougeard AM, Bedford M, Vallance A, Singh P, Vohra R, Ignacka A, Tucker O, Aresu G, Cripps M, Ellicott H, Samuel K, Chazapis M, Hunt AF, Lusby E, Durrand J, Weerasuriya S, PQIP Collaborative, Batchelor A, Snowden C, Murray D, Evans E, Vaux E, Abercrombie J, McGhie J, Dhesi J, Clark T, Crossley A, McGrath J, Digner M, Hamilton M, Hill R, Shinde S, Brett S.   +77 more
europepmc   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Ethnic minority patients' experiences of filling in translated patient-reported outcome measures. [PDF]

J Public Health Res
Alpers LM, Hanssen I.
europepmc   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source